摘要
终末期肝病唯一有效的治疗方式为肝移植,但价格昂贵、肝源短缺等原因限制了肝移植在临床上的实际应用,故改善生活质量及预后在终末期肝病患者的治疗中具有重要的意义。利福昔明作为一种难以被吸收的口服抗生素,对胃肠道具有良好的药理作用。可通过调节肠道微生物和免疫平衡及其代谢产物的生成、减少小肠细菌过度生长、维持肠道通透性和屏障功能等作用,从而直接或间接地在一定程度上延缓终末期肝病的发展、治疗或预防终末期肝病患者所并发的门静脉高压、肝性脑病、腹水、自发性腹膜炎、肝肾综合征、肌肉减少症等。本文就利福昔明在终末期肝病患者的应用及作用机制进行综述。
The only effective treatment for end-stage liver disease is liver transplantation. However, the high price and shortage of liver sources limit the practical clinical application of liver transplantation. Therefore, improving the quality of life and prognosis is of great significance in the treatment of pa-tients with end-stage liver disease. Rifaximin, as an oral antibiotic that is difficult to absorb, has good pharmacological effects on the gastrointestinal tract. It can directly or indirectly delay the de-velopment of end-stage liver disease to a certain extent by regulating intestinal microbial, immune balance and the production of metabolites, reducing small intestinal bacterial overgrowth, main-taining intestinal permeability and barrier function to treat or prevent portal hypertension, hepatic encephalopathy, ascites, spontaneous peritonitis, hepatorenal syndrome, sarcopenia, etc, in pa-tients with end-stage liver disease. This article reviews the application and mechanism of action of rifaximin in patients with end-stage liver disease.
出处
《临床医学进展》
2024年第1期466-475,共10页
Advances in Clinical Medicine
